

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

WOCKHARDT BIO AG,
Petitioner,

v.

JANSSEN ONCOLOGY, INC.,
Patent Owner.

Case IPR2016-01582
Patent 8,822,438

Held: May 24, 2017

BEFORE: LORA M. GREEN, RAMA G. ELLURU, and
KRISTINA M. KALAN, Administrative Patent Judges.

The above-entitled matter came on for hearing on Wednesday,
May 24, 2017, commencing at 2:26 p.m., at the U.S. Patent and
Trademark Office, 600 Dulany Street, Alexandria, Virginia.

Case IPR2016-01582
Patent 8,822,438

APPEARANCES:

ON BEHALF OF THE PETITIONER:

DENNIES VARUGHESE, ESQUIRE
LESTIN KENTON, ESQUIRE
Sterne, Kessler, Goldstein & Fox
1100 New York Avenue, N.W.
Washington, D.C. 20005

ON BEHALF OF PATENT OWNER:

DAVID T. PRITIKIN, ESQUIRE
BINDU DONOVAN, ESQUIRE
ALYSSA B. MONSEN, ESQUIRE
Sidley Austin, LLP
787 Seventh Avenue
New York, New York 10019

1 your demonstratives, please refer to them clearly by slide number
2 for our benefit as well as the benefit of the transcript.

3 Petitioner has the burden to show that the challenged
4 claims are unpatentable and thus will present its case first. Patent
5 owner will then argue its opposition to patent owner's [sic] case.
6 If petitioner has reserved any time, petitioner can use that time for
7 rebuttal. I'll give you a warning when you are reaching the end of
8 your argument time.

9 Does counsel have any questions, starting with
10 petitioner?

11 MR. VARUGHESE: No, Your Honor.

12 JUDGE ELLURU: And patent owner?

13 MR. PRITIKIN: No, Your Honor.

14 JUDGE ELLURU: Thank you. Counsel, you may
15 begin when you are ready. And would you like to reserve any
16 time for rebuttal?

17 MR. VARUGHESE: Yes, Your Honor. I would like to
18 reserve ten minutes for rebuttal. Your Honors, we have hard
19 copies of the slides, if we may approach.

20 JUDGE ELLURU: Yes, please.

21 MR. VARUGHESE: Thank you, Your Honor. Once
22 again, Dennies Varughese on behalf of petitioner, Wockhardt.
23 Your Honors, given the prior proceeding today and the *Amerigen*
24 proceeding a few months ago, Your Honors have heard a lot.
25 There's been a lot of papers submitted here. And in putting the

1 Wockhardt proceeding and trial on a fast track and compressed
2 schedule, I presume that the Board recognized that there's some
3 substantial overlap in the technology and the medical issues
4 involved in these multiple proceedings. So to the extent possible,
5 I'm going to try to avoid any redundancy in that regard and try to
6 focus on the Wockhardt-specific issues and specific disputes
7 between Wockhardt and Janssen. However, I am cognizant of the
8 need to have a complete record, so I will touch upon all the major
9 issues. And I'm happy to address any of the questions the Board
10 may have as I do that.

11 Turning to slide 2, this is an overview of our argument.
12 Simply put, Wockhardt submits that claims 1 through 20 of the
13 '438 patent would have been obvious over the combination of
14 Gerber, O'Donnell, and Sartor. I'm going to address some of
15 these points, but in their patent owner response Janssen has
16 advanced a number of arguments that it believes tries to rebut or
17 overcome this prima facie case, and for various reasons we
18 submit that they have not done so. Then finally, I'll close by
19 addressing some of the secondary considerations that Janssen has
20 advanced.

21 Turning to slide 4, in instituting the *Amerigen* trial, this
22 Board issued claim constructions for some terms that appear in
23 the claims of the '438 patent, namely "treat," "treating,"
24 "treatment," and "therapeutically effective amount of
25 prednisone." In Wockhardt's petition and in this trial, Janssen and

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.